secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0001503274-25-000065
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix completes Akoya acquisition for ~7.8M shares + $20M cash; TAM expands to $5B
--------------------------------------------------------------------------------

- Quanterix issued ~7.8M shares and paid ~$20M cash to buy Akoya, creating integrated blood & tissue biomarker platform.
- Combined addressable market grows from $1B to $5B; company expects accelerated path to profitability by 2026.
- CEO Masoud Toloue and CFO Vandana Sriram continue; new board members Scott Mendel and Myla Lai-Goldman appointed.
- Prior directors Martin Madaus and Sarah Hlavinka resigned effective at closing; cash balance ~$163M post-transaction.
- Historical financials of Akoya and pro forma financials to be filed within 71 days via 8-K/A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000150327425000065/0001503274-25-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000150327425000065/qtrx-20250708.htm
  HTML page:      https://secwatch.observer/filing/0001503274-25-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer